Jia Liu1, Lu-ning Wang. 1. Department of Geriatric Neurology, Chinese PLA General Hospital, Fuxing Road 28, Beijing, 100853, China.
Abstract
BACKGROUND: Neurodegenerative movement disorders mainly include Parkinson's disease (PD), atypical parkinsonisms, Huntington's disease (HD), and Friedreich's ataxia (FA). With mitochondrial dysfunction observed in these diseases, mitochondrial enhancement such as creatine, coenzyme Q10 (CoQ10) and its analogues (idebenone and mitoquinone) has been regarded as a potential treatment. AIM: In this paper, we systematically analysed and summarized the efficacy of mitochondrial enhancement in improving motor and other symptoms in neurodegenerative movement disorders. METHODS: We searched the electronic databases PubMed, EMBASE, CINAHL, Cochrane Library and China National Knowledge Infrastructure until September 2013 for eligible randomized controlled trials (RCTs), as well as unpublished and ongoing trials. We calculated the mean differences for continuous data with 95% confidence intervals and pooled the results using a fixed-effect model, if no significant statistical heterogeneity was found (I(2) < 50%). RESULTS: We included 16 studies with 1,557 randomized patients, which compared creatine, CoQ10 or its analogues with placebo in motor and other symptoms. No significant improvements were found in the motor symptoms of PD, atypical parkinsonisms or HD patients, while only the high dose of idebenone seems to be promising for motor improvement in FA. Certain benefits are found in other symptoms. CONCLUSIONS: There is insufficient evidence to support the use of mitochondrial enhancement in patients with neurodegenerative movement disorders. More well-designed RCTs with large samples are required for further confirmation.
BACKGROUND:Neurodegenerative movement disorders mainly include Parkinson's disease (PD), atypical parkinsonisms, Huntington's disease (HD), and Friedreich's ataxia (FA). With mitochondrial dysfunction observed in these diseases, mitochondrial enhancement such as creatine, coenzyme Q10 (CoQ10) and its analogues (idebenone and mitoquinone) has been regarded as a potential treatment. AIM: In this paper, we systematically analysed and summarized the efficacy of mitochondrial enhancement in improving motor and other symptoms in neurodegenerative movement disorders. METHODS: We searched the electronic databases PubMed, EMBASE, CINAHL, Cochrane Library and China National Knowledge Infrastructure until September 2013 for eligible randomized controlled trials (RCTs), as well as unpublished and ongoing trials. We calculated the mean differences for continuous data with 95% confidence intervals and pooled the results using a fixed-effect model, if no significant statistical heterogeneity was found (I(2) < 50%). RESULTS: We included 16 studies with 1,557 randomized patients, which compared creatine, CoQ10 or its analogues with placebo in motor and other symptoms. No significant improvements were found in the motor symptoms of PD, atypical parkinsonisms or HDpatients, while only the high dose of idebenone seems to be promising for motor improvement in FA. Certain benefits are found in other symptoms. CONCLUSIONS: There is insufficient evidence to support the use of mitochondrial enhancement in patients with neurodegenerative movement disorders. More well-designed RCTs with large samples are required for further confirmation.
Authors: Tamas L Horvath; Sabrina Diano; Csaba Leranth; Luis Miguel Garcia-Segura; Michael A Cowley; Marya Shanabrough; John D Elsworth; Peter Sotonyi; Robert H Roth; Edwin H Dietrich; Russel T Matthews; Colin J Barnstable; D Eugene Redmond Journal: Endocrinology Date: 2003-07 Impact factor: 4.736
Authors: S M Hersch; S Gevorkian; K Marder; C Moskowitz; A Feigin; M Cox; P Como; C Zimmerman; M Lin; L Zhang; A M Ulug; M F Beal; W Matson; M Bogdanov; E Ebbel; A Zaleta; Y Kaneko; B Jenkins; N Hevelone; H Zhang; H Yu; D Schoenfeld; R Ferrante; H D Rosas Journal: Neurology Date: 2006-01-24 Impact factor: 9.910
Authors: A Bender; W Koch; M Elstner; Y Schombacher; J Bender; M Moeschl; F Gekeler; B Müller-Myhsok; T Gasser; K Tatsch; T Klopstock Journal: Neurology Date: 2006-10-10 Impact factor: 9.910
Authors: F J Jiménez-Jiménez; J A Molina; F de Bustos; A García-Redondo; C Gómez-Escalonilla; A Martínez-Salio; A Berbel; A Camacho; M Zurdo; B Barcenilla; R Enríquez de Salamanca; J Arenas Journal: J Neural Transm (Vienna) Date: 2000 Impact factor: 3.575
Authors: Sarah J Lagedrost; Martin St John Sutton; Meryl S Cohen; Gary M Satou; Beth D Kaufman; Susan L Perlman; Christian Rummey; Thomas Meier; David R Lynch Journal: Am Heart J Date: 2011-01-31 Impact factor: 4.749
Authors: Alexander Storch; Wolfgang H Jost; Peter Vieregge; Jörg Spiegel; Wolfgang Greulich; Joachim Durner; Thomas Müller; Andreas Kupsch; Henning Henningsen; Wolfgang H Oertel; Gerd Fuchs; Wilfried Kuhn; Petra Niklowitz; Rainer Koch; Birgit Herting; Heinz Reichmann Journal: Arch Neurol Date: 2007-05-14
Authors: Beth Borowsky; John Warner; Blair R Leavitt; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Chris Becker; Cristina Sampaio; Allan J Tobin; Howard Schulman Journal: Neurology Date: 2013-04-24 Impact factor: 9.910